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Introduction: Need for permanent pacemaker (PPM) is a well recognised compli-
cation especially after transcatheter aortic valve implantation (TAVI) with CoreValve
(CV). Although this problem is not surprising when one considers the depth of
implantation of the CV prosthesis within the left ventricular outﬂow tract in previous
many studies, many operators don't prefer high implantation strategy (HIS). In this
single center retrospective study, we examined the need for PPM in patients who
underwent TAVI with the CV using HIS.
Methods: In our retrospective study,37 patients used HIS out of a total amount of 46
patients who underwent TAVI using the third generation CV prosthesis were identiﬁed
for this case series. During our initial experience, we positioned the ventricular edge of
the prosthesis 6-8 mm below the annular margin of the noncoronary leaﬂet. Then, we
decided to change our strategy and tried to implement HIS. The depth of implantation
in the LVOT was deﬁned as the distance between the annular margin of noncoronary
cusp and the proximal end of the prosthesis frame. If the depth of implantation is 4
mm, this was accepted as high implantation. The implantation depth of >4 mm was
deﬁned as normal or low implantation. In HIS, rapid pacing at 150–220 beat/min was
used to implant the valve optimally during the deployment of the CV.
Results: A total of 46 patients underwent TAVI with the CoreValve in our center
(mean age of 77.610.2 years,mean logistic EuroSCORE of 17.213.2, mean STS
score of 11.85.8, n¼44 transfemoral, n¼2 subclavian). As a result of two intra-
procedural deaths), procedural success was achieved in 2/46 patients (96%). The
mortality rate at 30 days and 1 year were 13% and 17%, respectively. In-hospital
stroke was 2.2%, major vascular complications and life-threatening bleedings due to
closure device failure was observed in 3 patients (6.5%). Closure of the femoral
arteriotomy using the Prostar (n¼10) or double Proglide devices (n¼34) was
successful in 41 cases (93%). Post-procedure aortic regurgitation (AR)  grade I was
present in 39 patients (84%), grade 2 AR was found in 5 patients (10%). After TAVI,
in 1/9 patients (11%) of normal depth of implantation required PPM implantation.
Despite our intentions to implant the prosthesis at a target depth of 4 mm, we were
not able to succeed in 6 (16%) of the patients who underwent HIS. With HIS, need for
PPM was documented in 2/37 patients (5.4%). Of the three patients with preexisting
right bundle branch block, one (33%) required PPM implantation after TAVI.
Conclusion: In previous studies on TAVI with the CV bioprosthesis, the reported rate of
PPM ranged from 9.3 to 42%. Thus, the 5.4% PPM rate reported at this study can be
considered to be one of the lowest observed thus far. Wide range in the rate of PPM
implantation in previous studiesmaydepend on the implantation strategy.AHIS at a target
depth of 4 mm below the annulus may decrease the PPM rate after TAVI with CV.
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Aortic stenosis (AS) prevalence increases with the elderly. They present high
surgical risk due to the comorbid factors increasing with the age. One of the comorbid
factors that increases the risk in patients is aortic aneurysm. It will increase the rupture
risk with the systolic pressure which will be increased with the aortic stenosis treated.
Hence, the timing and method of the both treatments are of great importance in our
high-risk case which is accompanied by thoracic aortic saccular aneurysm and serious
aortic stenosis. Transcatheter aortic valve implantation (TAVI) is an effective method
in the patients that present severe aortic stenosis with a higher surgical risk or that
cannot undergo surgical aortic valve replacement (s-AVR). A 83 years old male patient
with a history of coronary artery bypass grafting (CABG), and permanent pacemaker
(VVI-R type) following myocardial infarction six years ago was admitted to our clinic
as he had an increased dyspnea lately. Transthoracic echocardiography (TTE), severe
aortic stenosis were detected and left ventricular ejection fraction (EF) was detected as
35%. Multi-slice computed tomography (MSCT), 20x18 mm saccular aneurysm in the
thoracic aorta just after the left subclavian artery was detected by means of a detailed
review. Under general anesthesia, the patient who was taken to catheterization labo-
ratory was performed surgical cut-down from left femoral route ﬁrstly, he was per-
formed balloon valvuloplasty accompanied with TEE and then Edwards Sapien XT
(Edwards Lifesciences, Irvine, CA, USA) 26 mm valve implantation under the rapid
pacing through 18 Fr sheath. The procedure was evaluated as successful. Then, the
guide catheter was implanted over the stiff wire implanted for TAVI. A 0.035 inch
extra-stiff wire through the guiding catheter (Lunderquist, Cook, Inc.) was advanced to
the ascending aortic proximal gently enough not to touch the bioprosthesis aortic valve.
Then; over the extra-stiff wire, a 36x130 mm Zenith (Cook, Inc., Bloomington, Ind.)
thoracic stent-graft was placed just distal to the left subclavian artery. Notable
improvements in functional capacity was observed in the patient discharged 1 weekC34 JACC Vfollowing the procedure and taken into the follow-up. After 1 month, the patient had
good functional capacity and there was no complications control TTE and MSCT.
In this case which is, as far as we know, the ﬁrst and the only one in the literature;
both TAVI and endovascular thoracic aortic saccular aneurysm repair (TEVAR) were
applied simultaneously successfully to the patient via same transfemoral route. In this
way, we tried to emphasize with a multi disciplinary study that the patients be assessed
carefully before the procedure, that even the patients with common peripheral vascular
diseases transfemoral route could be used together with the proper methods, and that
both procedures could be performed simultaneously.ol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORALS
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Aim: Previous studies on outcome after transcatheter aortic valve implantation
(TAVI) have focused on the ﬁrst 30 days as well as ﬁrst year after the procedure.
Recently new left bundle branch block (LBBB) has been discussed to potentially have
a negative impact on long-term outcome. This study aimed at deﬁnition of the long-
term outcome up to 5 years after TAVI as well as the impact of new LBBB or need for
pacemaker implantation on outcome.
Methods: 376 consecutive patients with symptomatic aortic stenosis were prospec-
tively included. 205 patients were treated with a CoreValve prosthesis and 171
patients with an Edwards Sapien prosthesis. 167 patients developed a new LBBB or
needed a new pacemaker, in 209 patients neither a new LBBB was observed nor a new
pacemaker was required. Patients were followed-up on a yearly basis.
Results: Survival at 1 year follow-up was 81%, at two-year follow-up was 72%, at
three year follow-up 67% and at four year follow-up 60%. NHYA functional class
showed a marked improvement from 3.10.5 before TAVI to 1.80.7 at latest
follow-up. Impaired left ventricular function (ejection fraction <40%) before TAVI
was associated with impaired survival at follow-up (p¼0.012). There was no differ-
ence in long-term survival between patients with and without new LBBB or pace-
maker implantation (see ﬁgure).
Conclusion: Survival more than one year after TAVI is good with a yearly mortality
of less than 10%. A new LBBB or pacemaker implantation after TAVI has no negative
impact on long-term survival.C36 JACC VOP-081
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Introduction: Transcatheter aortic valve implantation (TAVI) has been a reliable
treatment modality for high risk patients with severe aortic stenosis (AS). TAVI has
high procedural success rates however some complications can occur during the
procedure. In this study, our aim is to present our experience with TAVI which is
a recently devoloping therapy in our country by demonstrating the clinical charac-
teristics of the patients and the complications related to the procedure.
Methods:We examined one month postprocedural results of 36 (20 women) high risk
patients with severe AS who had undergone TAVI in our clinic between 01 June 2012
and 31 May 2013. CoreValve (Medtronic Inc., Minneapolis, MN) or Edwards Sapien
XT (Edwards Lifesciences, Irvine, CA) bioprosthesis valves were implanted by
transfemoral approach to all parties.
Results: The mean age of the patients was 78.57.6 (range 55-91 years). Related
diseases of the patients and their risk scores are demonstrated in Table 1. Mean aortic
valve area was 0.60.1 cm2, and aortic valve gradients were 75.714.3 mmHg
(maximal) and 49.38.8 mmHg (mean). Femoral arterial access was achieved by
surgical cut down in 29 patients, and percutaneously (Prostar XL) in 7 patients (Table
2). Complications related to the procedure are demonstrated in Table 3. Two patients
(%5,6) had malapposition of bioprotesis into left ventricle and paravalvular aortic
regurgitation (AR) during the procedure requiring a second valve (CoreValve)
implantation. One patient had cardiac tamponade and treated with pericardiosentesis.
Vascular complication of femoral artery occurred in 5 (%13,9) of the patients
(Percutaneously Prostar XL was used in 3, and surgical cut down in 2 of patients).
Four patients need permanent cardiac pacemaker after TAVI (3 patients treated with
CoreValve, 1 patient with Edwards Sapien). Stroke occured in 1 patient who had
a second CoreValve bioprotesis due to malapposition of the ﬁrst bioprotesis. 3 (8,3%)
of the patients had paravalvular AR after TAVI. Ventricular septal defect which is
a rare complication after TAVI determined in 1 of the patients at the follow up period
treated with Edwards Sapien XT bioprotesis. There was no mortality during the
procedure, and at the 1 month follow-up period. However, at the 3 months of follow-
up 1 (0.02 %) cardiac death occured and 4 (11,1%) deaths observed due to noncardiac
causes (pneumonia, septic shock, renal failure, and head trauma).
Conclusion: TAVI is a reliable treatment modality alternative to surgery with low
incidence of complications, and high success rates for high-risk patients with severe
AS. Our experience is consisted with worldwide results. However there were rela-
tively low number of patients, the requirement of permanent pacemaker in CoreValve
procedures (11.54%) were lower than the reported incidence in literature.ol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORALS
